SIS
SRNE

Sound Income Strategies’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Sound Income Strategies’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15
Closed -$124 – 1079
2021
Q1 		$124 Buy
+15
New +$158 ﹤0.01% 936

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Sound Income Strategies's SRNE Position: Q2 2021 in Review

Sound Income Strategies sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2021, closing a stake of 15 shares — an estimated $124 sold.

Sound Income Strategies first reported a position in SRNE in Q1 2021 and held it in 1 quarter. The position peaked at $124 in Q1 2021. 212 funds tracked by Wall St. Rank hold SRNE as of Q2 2021.

  • Sound Income Strategies reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Sound Income Strategies sold 15 Sorrento Therapeutics, Inc. shares in Q2 2021, an estimated $124.
  • Sound Income Strategies first reported a position in Sorrento Therapeutics, Inc. in Q1 2021 and held it in 1 quarter.
  • Sound Income Strategies's Sorrento Therapeutics, Inc. position peaked at $124 in Q1 2021.
  • 212 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2021.

Based on Sound Income Strategies's 13F filing for Q2 2021, filed 13 Jul 2021.